The global Retinal Vein Occlusion Treatment market is expected to be valued US$ 2.3 billion in 2023, with a compound annual growth rate (CAGR) of 5.9% from 2023 to 2033, reaching US$ 4.7 billion. One of the most prevalent retinal vascular problems in the elderly is retinal vein occlusion, which affects persons over the age of 65. The risk of retinal vein blockage increases with age. As the geriatric population grows, the prevalence of retinal vein blockage is expected to climb. Retinal vein occlusion is one of the most common retinal vascular diseases in the elderly, affecting adults over the age of 65. Age is a substantial risk factor for retinal vein occlusion. As the elderly population goes up, it is presumed that the incidence of retinal vein occlusion will increase as well.
Request a Report Sample and Gain a Competitive Advantage@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16599
North America held a significant percentage of the global retinal vein occlusion market in 2022 due to numerous upgraded medical facilities, an increase in the occurrence of eye ailments, technological improvements, and an increase in the ageing population. The Asia Pacific retinal vein occlusion market is anticipated to grow at a 6.5% CAGR between 2023 and 2033. Rising ocular illness prevalence in Asia Pacific, particularly in China, Singapore, Indonesia, and other Southeast Asian countries, as well as rising health expenditures, are expected to drive market expansion in East and South Asia from 2023 to 2033. During the forecast years, Europe is expected to have the second-largest market share. The rise of a huge older population, along with elevated healthcare spending, is driving the retinal vein occlusion market expansion in this region.
The branch retinal vein occlusion segment had the highest global retinal vein occlusion therapeutics revenue growth in 2022. This segment is expected to dominate the market as the occurrence of high blood pressure, cardiovascular disease, and glaucoma rises.
Key Takeaways from the Market Study
- The global retinal vein occlusion treatment market is estimated to reach US$ 4.7 billion by 2033, with the East Asia retinal vein occlusion market expanding at a CAGR of 6.5%.
- Sales climbed dramatically at a CAGR of 5% between 2018 and 2022.
- According to a 2018 Pubmed report, the random-effects gathered chance of RVO among Europeans over the age of 55 was 0.7%.
- From 900,000 in 2018 to 1.1 million in 2050, the total number of affected people in the EU is predicted to nearly treble.
“Players in the Retinal Vein Occlusion Treatment domain are increasing their capacity to produce corticosteroid drugs, which can help combat the inflammatory factors that cause edema. Healthcare professionals, on the other hand, are becoming increasingly skilled in focal laser therapy,” says FMI’s analyst.
Ask More About This Market’s Geographical Distribution Along With a Detailed Analysis of the Top Regions@ https://www.futuremarketinsights.com/ask-question/rep-gb-16599
Market Competition
Key players in the Retinal Vein Occlusion Treatment market are AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Kodiak Sciences Inc., Chugai Pharmaceuticals, and Novartis AG among others.
- Novartis confirmed its strong support for the first interpretable Phase III outcomes of a clinical study assessing the efficacy and safety of Beovu in December 2020. Beovu by Novartis competed directly with Regeneron’s anti-VEGF Eylea, one of the most well-known treatments for diabetic macular edoema.
- Roche is now conducting Phase III trials to assess the efficacy and safety of Faricimab in patients with macular edoema secondary to BRVO and CRVO, with the medicine expected to be licenced by 2023 based on the results.
More Valuable Insights Available
North America is currently the largest Retinal Vein Occlusion Therapy market, primarily due to the high prevalence of retinal diseases in the region. The United States is a significant contributor to the North American market, with a growing demand for effective Retinal Vein Occlusion Treatments and increasing investment in research and development.
Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/16599
Key Segments Profiled in the Retinal Vein Occlusion Treatment Industry Survey
By Drug Class:
- Ranibizumab
- Dexamethasone
- Aflibercept
- Bevacizumab
By Type:
- Central Retinal Vein Occlusion
- Branch Retinal Vein Occlusion
By Diagnosis:
- Optical Coherence Tomography
- Fundoscopic Examination
- Fluorescein Angiography
By End User:
- Hospitals
- Research and Academics
- Specialty Clinics
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
